Clinical trial
A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection
NCT04596319 is registered in ClinicalTrials.gov with Armata Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection
- Lead sponsor
- Armata Pharmaceuticals, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 22, 2020
- Completion date
- December 14, 2022
- Enrollment
- 29 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
cystic fibrosis, lung infection, lung infection pseudomonal, pseudomonas, pseudomonas aeruginosa